ACC joins with World Congress of Cardiology to highlight breaking CV science
Click Here to Manage Email Alerts
The 2023 American College of Cardiology Scientific Session will be held live in New Orleans from Saturday to Monday and virtually, with 43 late-breaking trials and featured clinical research presentations.
This year, ACC is partnering with the World Heart Federation (WHF)/World Congress of Cardiology (WCC) as part of an effort to bring a more global perspective to CV research. This year’s scientific session program will reflect that global perspective, with joint presentations on a range of topics with international impact.
“The last time the ACC was in New Orleans was in 2019, so this is a great homecoming,” Douglas E. Drachman, MD, FACC, Corrigan Minehan Heart Center director of education, Teresa G. and Ferdinand F. Martignetti Endowed Chair for cardiovascular medicine at Massachusetts General Hospital and chair of the 2023 Scientific Session, said during a press conference before the meeting. “We can all appreciate the diversity of culture in New Orleans, and the true international influence mirrors many of the objectives we all share for ACC 2023 together with the WCC.”
Program with ‘distinct international flavor’
ACC/WCC 2023 embodies a partnership with the WHF that included international representation during the planning as well as an effort to showcase international CVD prevention strategies throughout the planning process, according to Drachman.
“Our focus on global health and international perspective, therefore, is truly baked into the entire conference,” Drachman said during the press conference. “This partnership also emphasizes ACC’s mission to transform CV care and improve heart health all across the world. There is a distinct international flavor that is peppered throughout the entire meeting.”
Some examples will include the WHF’s “Heart Café,” located in the convention center’s Lounge and Learn Pavilion, where WHF members will host seven interactive educational sessions focused on CVD, noncommunicable disease and global health. Sessions throughout the meeting will also include a focus on the global burden of CVD, Drachman said.
During the 3-day meeting, in-person and virtual attendees can join more than 300 education sessions, 11 learning pathways, 12 guideline-specific sessions and six virtual channels.
Interactive sessions at this year’s Heart2Heart stage will feature 17 sessions on topics ranging from leadership, health equity, global collaboration and topics such as CV care of women in the post-Dobbs era. An ACC 2023/WCC intensive focused on critical care cardiology, led by co-chairs Robert Roswell, MD, FACC, and David M. Dudzinski, MD, JD, FACC, includes eight presentations addressing cardiogenic shock, global approaches to cardiac arrest care, case presentations and debates.
More than 6,000 abstracts were submitted for presentation at the session and 4,000 from 84 countries were accepted.
“We feel that this has been an outstanding year for science at ACC 2023/WCC,” Drachman said during the press conference. “This is outstanding; it represents a 24% increase in the number of submissions since just last year, and it is the greatest number of abstract submissions we have seen since 2004.”
Five keynote presentations will also take place at the upcoming meeting:
- the Louis F. Bishop keynote with Susanna Price, MD, PhD, on Saturday at noon CDT: “The Evolution of the Cardiac ICU: The Present is not the Past nor Can It Be the Future”;
- the Kanu and Docey Chatterjee keynote with Clyde W. Yancy, MD, MACC, on Sunday at 8 a.m. CDT: “2022 Heart Failure Guidelines ... What Is Needed”;
- the Dan G. McNamara keynote with Daniel J. Murphy, MD, FACC, on Sunday at 12:15 p.m. CDT: "Well-being and Professional Fulfillment: Whose Job Is It Anyway?”;
- the Douglas P. Zipes Distinguished Young Scientist keynote with Michael Honigberg, MD, FACC, on Sunday at 2 p.m. CDT, “Toward Precision Prevention of Cardiovascular Disease in Women”; and
- the Eugene Braunwald keynote with Elizabeth M. McNally, MD, PhD, on Monday at 12:45 p.m. CDT, “Genetic Testing and Genetic Therapies for Cardiomyopathy.”
Late-breaking science
The meeting will feature 23 late-breaking clinical trials across five sessions, as well as 20 presentations from three featured clinical research sessions and a new “clinical and investigative horizons” session, which will highlight cutting-edge CV research.
Select late-breaking science scheduled to be presented at ACC includes:
- the CLEAR Outcomes trial, which assessed CV outcomes among statin-intolerant patients randomly assigned bempedoic acid (Nexletol, Esperion Therapeutics) or placebo;
- TRILUMINATE, the first randomized trial to show outcomes of treatment of severe tricuspid regurgitation with transcatheter tricuspid valve edge-to-edge repair (TriClip, Abbott);
- ACCESS, a study assessing the impact of eliminating copays for high-value medicines among older adults with low incomes;
- FREEDOM COVID, looking at the optimal strategies for anticoagulation among patients hospitalized with COVID-19;
- the Return to Play for Elite Athletes study, assessing when, or if, it is safe for athletes to return to play after a sudden cardiac arrest; and
- treatment of pulmonary arterial hypertension in the STELLAR trial.
The clinical and investigative horizons session, taking place Sunday at 2 p.m. CDT, will feature research on the prediction of preeclampsia using high-sensitivity troponin I, equitable access to point-of-care decentralized clinical trials, and CVD and mortality in Black women carrying a specific genetic variant.
“These [sessions] serve as food for thought for all of us to begin to think about as the evolving field of cardiology moves forward,” Kathryn L. Berlacher, MD, MS, FACC, assistant professor of medicine at University of Pittsburgh Medical Center (UPMC), associate chief of cardiology for education and program director of the cardiology fellowship program at UPMC Heart and Vascular Institute, and vice chair of the 2023 ACC Scientific Session, said during the press conference. “These are all fascinating topics to discuss.”
Healio | Cardiology Today will be onsite in New Orleans to report the latest news from the ACC Scientific Session, with physician perspective, researcher interviews and more. Follow our breaking updates here and by following @CardiologyToday on Twitter.
Collapse
Healio Coverage
Click Here to Manage Email Alerts